Bionano Genomics 

0
1086
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30JulExpected
Q1 2026
Next
-0.75
-0.7
-0.65
-0.6
Expected EPS
-0.6000737
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 2Y3.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pacific Biosciences of California
PACB
Mkt Cap521.81M
Pacific Biosciences offers long-read sequencing technologies that compete with Bionano's optical genome mapping solutions for complex genetic research and diagnostics.
Illumina
ILMN
Mkt Cap28.55B
Illumina provides sequencing and array-based solutions for genetic analysis, directly competing in the genomics market space that Bionano targets.
Thermo Fisher Scientific
TMO
Mkt Cap194.52B
Thermo Fisher Scientific offers a broad range of instruments and reagents for genomic research, including next-generation sequencing, competing with Bionano's genomic analysis technologies.
Agenus
AGEN
Mkt Cap126.18M
Agilent Technologies provides instruments, software, services, and consumables for the entire laboratory workflow, including genomics research, competing with Bionano's offerings.
Qiagen NV
QGEN
Mkt Cap8.07B
Qiagen offers sample to insight solutions, including next-generation sequencing and molecular diagnostics that compete with Bionano's genomic analysis solutions.
Intellia Therapeutics
NTLA
Mkt Cap2.45B
Intellia Therapeutics is involved in CRISPR/Cas9 technology for genome editing, which competes indirectly with Bionano's genomic mapping and analysis technologies by offering alternative approaches to genetic research and diagnostics.
Editas Medicine
EDIT
Mkt Cap560.14M
Editas Medicine operates in the genome editing space using CRISPR technology, offering a competitive alternative to Bionano's genomic analysis and mapping solutions.
CRISPR Therapeutics
CRSP
Mkt Cap5.92B
CRISPR Therapeutics is focused on developing gene-based medicines using CRISPR/Cas9 technologies, indirectly competing with Bionano's genomic analysis tools by providing alternative methods for genetic research.
Twist Bioscience
TWST
Mkt Cap6.18B
Twist Bioscience operates in the synthetic biology and genomics field, producing synthetic DNA that is used in genetic research, competing with Bionano's genomic analysis and mapping technologies.

About

Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles. The Saphyr platform includes the Saphyr instrument, a device capable of imaging single molecules; the Saphyr Chip, a disposable component equipped with nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide essential reagents and protocols for extracting and tagging ultra-high molecular weight DNA. Furthermore, Bionano Genomics supplies Saphyr and Bionano compute servers to support its analytical operations. It also offers NxClinical, a single software system designed for the analysis and interpretation of genomic variants identified through microarray and next-generation sequencing data, serving both cytogenetics and molecular genetics applications. In addition to its product line, Bionano Genomics delivers a variety of specialized testing and laboratory services. These include: FirstStepDx PLUS: A chromosomal microarray service used to identify underlying genetic causes in individuals with autism spectrum disorder, developmental delay, and intellectual disability. Fragile X syndrome (FXS) testing services: Comprehensive diagnostic testing for FXS. NextStepDx PLUS: An exome sequencing test aimed at detecting genetic variants associated with childhood developmental disorders. EpiPanelDx PLUS: A genetic testing panel for patients experiencing seizures, infantile spasms, encephalopathy, or febrile seizures. PGx test: A pharmacogenomics test that identifies over 60 alleles across 11 genes relevant to drug response. Bionano Genomics was founded in 2003 and operates from its corporate headquarters in San Diego, California.
Show more...
CEO
Dr. Albert A. Luderer Ph.D.
Employees
98
Country
United States
ISIN
US09075F1075

Listings

0 Comments

Share your thoughts

FAQ

What is Bionano Genomics stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Bionano Genomics stocks are traded under the ticker 2Y3.MU.
When is the next Bionano Genomics earnings date?
Bionano Genomics is going to release the next earnings report on July 30, 2026.
What were Bionano Genomics earnings last quarter?
2Y3.MU earnings for the last quarter are -0.65 EUR per share, whereas the estimation was -0.75 EUR resulting in a +13.64% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Bionano Genomics have?
As of July 12, 2026, the company has 98 employees.
In which sector is Bionano Genomics located?
Bionano Genomics operates in the Health & Wellness sector.
When did Bionano Genomics complete a stock split?
Bionano Genomics has not had any recent stock splits.
Where is Bionano Genomics headquartered?
Bionano Genomics is headquartered in San Diego, United States.